博瑞医药(688166.SH)：参与全国药品集中采购拟中标

Core Viewpoint - 博瑞医药's subsidiary, 博瑞制药, participated in the 11th national centralized drug procurement organized by the National Organization for Drug Procurement Office, with its product, Dydrogesterone tablets, expected to win the bid [1] Group 1 - 博瑞医药's full ownership of 博瑞制药 is confirmed, indicating a strong corporate structure [1] - The participation in the national centralized procurement reflects the company's strategic approach to expand its market presence [1] - The expected bid win for Dydrogesterone tablets may enhance the company's revenue and market share in the pharmaceutical sector [1]